# Xenon (XENE) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/XENE
## Company Profile
- Ticker: XENE
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Canada
- Tags: CNS
## Stock Data
- Close: 64.3 USD
- Market cap: 5055608265 USD
- Last updated: 2026-08-05
## Business Overview
### Ion-Channel Therapeutics
Xenon Pharmaceuticals develops medicines that modulate neuronal ion channels. Its pipeline addresses epilepsy, depression and pain through mechanisms intended to control abnormal electrical signaling.
### Azetukalner
Azetukalner is a selective Kv7 potassium-channel opener intended to reduce excessive neuronal firing. It is the company's lead late-stage candidate across epilepsy and mood disorders.
### Epilepsy Programs
Positive X-TOLE2 results support a planned U.S. submission in focal-onset seizures. Additional Phase 3 studies cover focal-onset seizures outside the United States and primary generalized tonic-clonic seizures.
### Depression Programs
The X-NOVA studies evaluate azetukalner in major depressive disorder, while X-CEED extends the program into bipolar depression.
### XEN1701
XEN1701 is a NaV1.7 inhibitor in Phase 1 development as a potential non-opioid treatment for acute pain.
### XEN1120
XEN1120 is a separate Kv7 modulator in Phase 1 testing for pain, providing a second ion-channel mechanism outside the azetukalner franchise.
## Why The Stock Is Moving

The latest monitored company update is “Xenon Reports Q2 2026 Financial Results and Provides Business Update.” The corresponding closing-price reaction is not yet available.

## Future Catalysts

- NDA submission for azetukalner in focal-onset seizures in the third quarter of 2026.
- Completion of Phase 1 studies of XEN1701 and XEN1120 in the second half of 2026.
- Topline Phase 3 X-NOVA2 data for azetukalner in major depressive disorder in the first half of 2027.

## Recent News
- 2026-08-06 20:01 EST — [Xenon Reports Q2 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/XENE/xenon-reports-q2-2026-financial-results-and-provides-business-update-5005aa04) — Source: Xenon
- 2026-07-31 20:01 EST — [Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/XENE/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-f69791eb) — Source: Xenon
- 2026-07-30 20:01 EST — [Xenon to Report Q2 2026 Financial Results on August 6, 2026](https://biopharmsignal.com/news/XENE/xenon-to-report-q2-2026-financial-results-on-august-6-2026-3b8e2d4f) — Source: Xenon
- 2026-05-07 20:01 EST — [Xenon Reports Q1 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/XENE/xenon-reports-q1-2026-financial-results-and-provides-business-update) — Source: Xenon
- 2026-04-30 20:01 EST — [Xenon to Report Q1 2026 Financial Results on May 7, 2026](https://biopharmsignal.com/news/XENE/xenon-to-report-q1-2026-financial-results-on-may-7-2026) — Source: Xenon